Testing a Mobile Health App to Improve Quality of Life in Black Men with Prostate Cancer
Led by University of Oklahoma · Updated on 2026-04-01
248
Participants Needed
3
Research Sites
56 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating a culturally tailored mobile health application designed for ethnically diverse Black men with prostate cancer, including those currently undergoing treatment or survivors. The study aims to see if the app is easy to use and helpful in improving quality of life by providing relevant information, symptom monitoring, and shared patient experiences. This study is interventional and randomized, focusing on quality-of-life outcomes over 12 months.
Participants are divided into two groups one completes scheduled electronic surveys at the start and at 3, 6, 9, and 12 months to assess quality of life. The other group also completes these surveys but gets access to the mobile app to use at home for 12 months. App users will answer daily symptom and activity surveys and weekly mood assessments for the first 3 months, receive educational content, and provide feedback through interviews after 12 months.
Throughout the study, all participants will complete online surveys to measure overall quality of life. App users have additional monitoring of symptoms, diet, physical activities, and mood via the app. Feedback interviews help improve the apps design. The studys primary measure is the overall quality of life of Black men with prostate cancer, tracked at 12 months. Participation involves regular surveys and app use if assigned to that group.
CONDITIONS
Brief Title
Using a mHealth App to Improve Quality-of-Life Outcomes in Black Prostate Cancer Survivors
Research Team
M
Motolani Adedipe, PhD, DPh, MS
P
Parisa Ghasemi, MD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
Factors
Surveys and mHealth App access
Surveys for Quality of Life
What it is
A tailored mobile health app used at home for 12 months alongside scheduled quality‑of‑life surveys
Scheduled electronic quality‑of‑life surveys at baseline and months 3, 6, 9, and 12
Primary use
Support symptom tracking, provide educational content, and enhance quality‑of‑life monitoring
Assess overall quality of life through periodic electronic surveys
Evidence status
Efficacy not yet established; study is evaluating feasibility, usability, and impact on quality of life
Standard survey‑only approach; existing evidence on impact of QoL surveys is routine but not sufficient as intervention
Important limitations
Digital access or literacy may vary among participants, impacting app use and engagement
Surveys alone may not engage users or support self‑management beyond assessment
Patient impact
Not yet known
Not yet known
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
Who Can Participate
Age: 18Years +
MALE
Eligibility Criteria
You may qualify if you...
Ethnically-diverse Black prostate cancer survivors who are native-born, Caribbean-born, or African-born
You will not qualify if you...
Men from other races
Men who have never been diagnosed with prostate cancer
Men who cannot speak English
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Enrollment and Baseline Assessment
Duration - 1 day
Participants complete baseline electronic surveys to assess quality of life and, for those in the app group, attend an initial study visit to review app use.
1 baseline visit (in-person or virtual)
Treatment
Duration - 12 months
Participants in the app group use the mobile application at home for 12 months, completing daily symptom surveys and weekly mood assessments for the first 3 months, with educational content provided through the app. Participants in the control group complete scheduled electronic surveys only.
Daily and weekly surveys for 3 months (app group); Scheduled surveys at months 3, 6, 9, and 12 (all participants)
Follow-up Interview
Duration - 1 day
At the end of 12 months, participants using the app participate in an interview to provide feedback on their experience with the app.
1 interview visit (app group)
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
SUPPORTIVE_CARE
Number of Arms
2
Similar Trials
Study of 177Lu-PSMA as an Additional Treatment for High and Very High Risk Prostate Cancer After Radiation and Hormone Therapy
Phase 1b Study of 177Lu-PSMA-617 With Liver-Directed Therapy for Metastatic Castration-Resistant Prostate Cancer
Using 18F-PSMA-1007 PET-CT to Guide Targeted Focal Therapy for MRI-Invisible Prostate Cancer
A Prospective Phase II Study Evaluating PET-Directed Treatment in Men with Localized Intermediate-Risk Prostate Cancer
Evaluation of 18F-PSMA-1007 PETCT Imaging Safety and Effectiveness in Adult Men with Prostate Cancer
Combining One MR-Guided HDR Brachytherapy and One SABR Treatment
for Favorable Risk Prostate Cancer
in a Phase 23 Study
Study of 4-Aminopyridine to Improve Nerve Recovery After Robot-Assisted Radical Prostatectomy in Men with Prostate Cancer
Phase III Study of 64Cu-GRIP B PET Imaging for Detecting Granzyme B in Adults with Advanced Genitourinary and Other Solid Tumors
Comparison of 68Ga-P16-093 and 68Ga-PSMA-11 PETCT Scans for Detecting Primary Prostate Cancer in Men
Using 68Ga-PSMA PETMRI and mpMRI to Detect Prostate Cancer in Men Aged 40 to 85
Observational Study to Compare Diagnostic Accuracy and Follow-Up Outcomes
PETCT Imaging Using 68Ga-RM26-RGD to Detect Breast, Brain, and Prostate Tumors with GRPR and v3 Receptors
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
A Culturally Tailored Mobile Health Intervention to Improve Quality of Life in Black Survivors With Prostate Cancer: Protocol for a Stratified Randomized Controlled Trial.